Sentence examples for for additional efficacy from inspiring English sources

Furthermore, most participating neonatologists agreed upon the need for additional efficacy data on prophylactic fluconazole, as expressed in the 2004 US survey [ 5].

Both active dose groups showed similar effectiveness for additional efficacy endpoints including creatinine clearance, SCr ratio and serum cystatin C, compared to those of the placebo group.

In fact, the highest average importance attributed was 3.3 and concerned two factors: the need for a statement by pediatric societies supporting the selection of the drug and the need for additional efficacy studies.

Overall, the items that were considered as most influential on the decision to use or not to use fluconazole prophylaxis were the NICU's incidence of candidiasis, the risk of increasing drug resistance related to its widespread use and the need for additional efficacy studies.

This survey gives evidence on how widely prophylaxis administration modalities vary across European NICUs and highlights three key factors influencing the prophylaxis decision process: the local incidence of candidiasis, the potential risk of increasing antifungal resistance and the need for additional efficacy trials.

The need for a statement by pediatric societies in support of the routine use of fluconazole for prophylaxis and the need for additional efficacy studies were also considered important factors (average importance, from 1 to 5: 3.5 and 3.3, respectively) [See Additional file 1 for data].

As the previous class of analogs, exemplified by JI-38, had shown promising results in multiple fields including cardiology, diabetes and wound healing, our new, more potent, GHRH agonists should manifest additional efficacy for possible medical applications.

For PHiD-CV, an additional efficacy against hospitalized all-cause pneumonia (1.068%) was also included to account for the vaccine's potential efficacy against NTHi.

In our opinion, application of this novel methodology provides an additional efficacy endpoint option for clinical studies where stabilization of disease is a clinically relevant endpoint.

However, G-BA did not agree with IQWiG regarding the additional efficacy benefit and decided for a significant additional benefit in terms of efficacy and a total score of marginal additional benefit.

Mean improvements from baseline for additional secondary efficacy endpoints including CDAI and SDAI (CT-P13 (25.2 and 25.8) vs INX (23.6 and 24.4) at week 30, respectively) were equivalent at weeks 14 and 30 between treatment groups (table 2).